Advanced Biomed (ADVB) vs Exagen (XGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Exagen (XGN) has outperformed Advanced Biomed (ADVB) over the past year, losing 25.6% versus a loss of 34.9%. Exagen is the larger company by market cap ($197.9 million vs $10.1 million), about 19.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADVB | XGN |
|---|---|---|
| Share price | $6.12 | $8.17 |
| Market cap | $10.11M | $197.92M |
| 1-day change | -2.86% | -1.57% |
| YTD return | +4.79% | +34.38% |
| 1-year return | -34.89% | -25.59% |
| 5-year return | — | -35.31% |
| P/E ratio (TTM) | 1.26 | — |
| EPS (TTM) | $4.85 | $-0.80 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $24.23 | $12.23 |
| 52-week low | $3.61 | $2.59 |
| Distance from 52-week high | -74.74% | -33.20% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +24.11% |
| Average volume | 1.75M | 328.42K |
| Shares outstanding | 1.65M | 24.23M |
| Employees | 31 | 216 |
| Sector | Healthcare | Health Care |
| Industry | Diagnostics & Research | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Exagen is about 19.6 times larger than Advanced Biomed by market value ($197.92M vs $10.11M).
- The two companies sit in different sectors: Advanced Biomed in Healthcare and Exagen in Health Care.
About Advanced Biomed
ADVB stock →Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, an automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cell (CTC) single-cell capture device; and A+CellScan, an analyzer with an immunostaining chip for immunostaining/analysis of the AC-1000 product.
Healthcare · Diagnostics & Research · 31 employees
About Exagen
XGN stock →Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States.
Health Care · Medical Specialities · 216 employees
ADVB vs XGN FAQ
Which is bigger, Advanced Biomed or Exagen?
Exagen (XGN) is larger, with a market capitalization of $197.92M compared with $10.11M for Advanced Biomed (ADVB).
Which stock has performed better over the past year, ADVB or XGN?
XGN returned -25.59% over the past 12 months, compared with -34.89% for ADVB (price return, excluding dividends). Past performance does not predict future results.
Are Advanced Biomed and Exagen in the same industry?
No. Advanced Biomed is in the Healthcare sector, while Exagen is in Health Care.